Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Controversies in prostate cancer radiotherapy: consensus development.

H Lukka1, P Warde, T Pickles

  • 1Hamilton Regional Cancer Centre, Ontario, Canada.

The Canadian Journal of Urology
|September 21, 2001
PubMed
Summary

Canadian radiation oncologists established consensus on localized prostate cancer treatment, defining risk groups and recommending conformal radiotherapy. Brachytherapy lacks sufficient trial evidence, but permanent seed implants are acceptable for low-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

Brachytherapy for high grade prostate cancer induces distinct changes in circulating CD4 and CD8 T cells - Implications for systemic control.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

Silo Experience.

Hall's journal of health·2022
Same author

Bladder Cancer: New Insights Into Dose, Volume and Prognostic Biomarkers.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

Treatment Outcomes of Low-grade Lymphoma of the Orbit.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urology

Background:

  • The GU Radiation Oncologists of Canada (GUROC) convened in 2000 to address controversial aspects of localized prostate cancer management.
  • Key areas included risk stratification, conformal radiotherapy, brachytherapy, and combined hormonal and radiation therapy.

Framework:

  • Established three risk groups (low, intermediate, high) for localized prostate cancer based on clinical stage, Gleason score, and PSA levels.
  • Recommended conformal radiotherapy techniques for patients undergoing prostatic radiotherapy, supported by toxicity data from randomized controlled trials.

Implementation:

  • Consensus reached on dose escalation strategies for each risk group.
  • Brachytherapy is not recommended over standard therapies due to insufficient randomized trial evidence, though non-randomized studies show promise.

Related Experiment Videos

  • Permanent seed implants considered acceptable for low-risk prostate cancer outside clinical trials.

    • Implications:

    • High-risk patients should receive prolonged adjuvant hormonal therapy (2-3 years), potentially with neoadjuvant hormonal therapy.
    • Adjuvant hormonal therapy is not routinely advised for low- and intermediate-risk patients.
    • Neoadjuvant hormonal therapy benefits bulky tumors; its role in other intermediate/low-risk cases requires further study.